Tags

Type your tag names separated by a space and hit enter

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Neurodegener Dis Manag. 2019 04; 9(2s):3-7.ND

Abstract

Postapproval studies have an essential role in demonstrating that an intervention is effective and well tolerated during use in daily clinical practice. Numerous large observational and registry studies of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray have been conducted subsequent to its approval in Europe in 2011. Collectively, these studies provide valuable insight into various aspects of THC:CBD spray during real-world use in patients with multiple sclerosis spasticity, including its long-term effectiveness and tolerability. The Italian Medicines Agency's web-based registry is the largest observational study of THC:CBD oromucosal spray conducted to date, reporting on more than 1600 patients prescribed THC:CBD spray since it was introduced in Italy in 2013, and further supporting its effectiveness and tolerability profile.

Authors+Show Affiliations

Department 'GF Ingrassia', Section of Neurosciences, Multiple Sclerosis Center, University of Catania, Catania, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30657027

Citation

Patti, Francesco. "Newest Evidence for Tetrahydrocannabinol:cannabidiol Oromucosal Spray From Postapproval Pragmatic Studies." Neurodegenerative Disease Management, vol. 9, no. 2s, 2019, pp. 3-7.
Patti F. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegener Dis Manag. 2019;9(2s):3-7.
Patti, F. (2019). Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegenerative Disease Management, 9(2s), 3-7. https://doi.org/10.2217/nmt-2018-0049
Patti F. Newest Evidence for Tetrahydrocannabinol:cannabidiol Oromucosal Spray From Postapproval Pragmatic Studies. Neurodegener Dis Manag. 2019;9(2s):3-7. PubMed PMID: 30657027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. A1 - Patti,Francesco, Y1 - 2019/01/18/ PY - 2019/1/19/pubmed PY - 2020/8/19/medline PY - 2019/1/19/entrez KW - THC:CBD oromucosal spray KW - multiple sclerosis spasticity KW - pragmatic studies SP - 3 EP - 7 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 9 IS - 2s N2 - Postapproval studies have an essential role in demonstrating that an intervention is effective and well tolerated during use in daily clinical practice. Numerous large observational and registry studies of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray have been conducted subsequent to its approval in Europe in 2011. Collectively, these studies provide valuable insight into various aspects of THC:CBD spray during real-world use in patients with multiple sclerosis spasticity, including its long-term effectiveness and tolerability. The Italian Medicines Agency's web-based registry is the largest observational study of THC:CBD oromucosal spray conducted to date, reporting on more than 1600 patients prescribed THC:CBD spray since it was introduced in Italy in 2013, and further supporting its effectiveness and tolerability profile. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/30657027/Newest_evidence_for_tetrahydrocannabinol:cannabidiol_oromucosal_spray_from_postapproval_pragmatic_studies_ L2 - https://www.futuremedicine.com/doi/10.2217/nmt-2018-0049?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -